Investigational drug · Phase 3
BAT1706
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Malignancies.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
44
Any phase or sponsor naming "BAT1706"
First trial start
2019
Dec 19, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BAT1706", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Malignancies
Largest trials
Live from ClinicalTrials.gov: studies naming "BAT1706" as an intervention, largest first.
- Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast CancerPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT00433511 · 4,994 participants · Start Nov 2, 2007 · Primary completion Jan 7, 2014
Drug: Bevacizumab; Cyclophosphamide and 2 more · For: Breast Adenocarcinoma
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 842 sites in all
- Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00217737 · 2,431 participants · Start Sep 6, 2005 · Primary completion Feb 22, 2024
Drug: Bevacizumab; Fluorouracil and 2 more · For: Colon Adenocarcinoma; Stage IIA Colon Cancer AJCC v7; Stage IIB Colon Cancer AJCC v7 and 1 more
Sites: Anniston, Alabama; Birmingham, Alabama; Huntsville, Alabama · 928 sites in all
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By SurgeryPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00324805 · 1,501 participants · Start Jul 19, 2007 · Primary completion Oct 20, 2015
Drug: Bevacizumab; Cisplatin and 4 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 and 1 more
Sites: Anniston, Alabama; Huntsville, Alabama; Mobile, Alabama · 1,169 sites in all
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube CancerPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT00565851 · 1,052 participants · Start Dec 6, 2007 · Primary completion Apr 30, 2019
Drug: Bevacizumab; Carboplatin and 3 more · For: Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma and 22 more
Sites: Anchorage, Alaska; Hot Springs, Arkansas; Auburn, California · 709 sites in all
- Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerPivotal-lookingRecruiting
NRG OncologyAcademic, hospital or other
NCT06580314 · 880 participants (planned) · Start Mar 12, 2025 · Primary completion Dec 31, 2034
Drug: Bevacizumab; Olaparib · For: Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor and 9 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 709 sites in all
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT01167712 · 692 participants · Start Oct 12, 2010 · Primary completion Dec 1, 2015
Drug: Bevacizumab; Carboplatin and 1 more · For: Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma and 27 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 563 sites in all
- A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung CancerPivotal-lookingCompleted
Bio-Thera SolutionsIndustry
NCT03329911 · 651 participants · Start Oct 20, 2017 · Primary completion Nov 5, 2019
Drug: EU Avastin®; BAT1706 and 2 more · For: Non-squamous Non-small Cell Lung Cancer
Sites: Xiamen, China; Orizaba, Mexico; Bloemfontein, South Africa · 5 sites in all
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialPivotal-lookingRecruiting
City of Hope Medical CenterAcademic, hospital or other
NCT07288034 · 535 participants (planned) · Start May 1, 2026 · Primary completion Oct 8, 2028
Drug: Adagrasib; Anti-PD-L1 Monoclonal Antibody and 5 more · For: Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8
Sites: Goodyear, Arizona; Corona, California; Duarte, California · 13 sites in all
- Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by SurgeryPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00861705 · 454 participants · Start Jul 21, 2009 · Primary completion Aug 1, 2014
Drug: Bevacizumab; Carboplatin and 3 more · For: Male Breast Carcinoma; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7 and 2 more
Sites: Jonesboro, Arkansas; Rogers, Arkansas; Berkeley, California · 448 sites in all
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT02839707 · 444 participants · Start Jun 23, 2017 · Primary completion May 9, 2023
Drug: Atezolizumab; Bevacizumab and 1 more · For: Fallopian Tube High Grade Serous Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Ovarian Seromucinous Carcinoma and 16 more
Sites: Anchorage, Alaska; Fairbanks, Alaska; Goodyear, Arizona · 919 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma.
Ren Z, Huang Y, Guo Y, et al. · Cancer Immunol Immunother 2026
- Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study.
Chen L, Rangel JDG, Cil T, et al. · Cancer Med 2023
- Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab.
Cao D, Deng C, Wang G, et al. · Drugs R D 2023
- A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin®) in Healthy Male Subjects.
Wu X, Wynne C, Xu C, et al. · BioDrugs 2019
- Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects.
Zhang H, Li Q, Zhu X, et al. · Cancer Chemother Pharmacol 2018
Also in development for Advanced Malignancies
- LBL-007AlcestobartPhase 38 trials
BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
- GimistotugBGB-A445Phase 34 trials
BeOne Medicines (BeiGene) · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma
- PelabresibDAK539, CPI-0610Phase 34 trials
Novartis · Myelofibrosis, Primary Myelofibrosis, Primary Myelofibrosis (PMF)
- TQB2930Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · HER2-positive Advanced Breast Cancer, Colorectal Cancer, Metastatic Breast Cancer
- TQB3616Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
- BGB-15025Phase 33 trials
BeOne Medicines (BeiGene) · Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Advanced Malignancies
- SurzebiclimabBGB-A425Phase 33 trials
BeOne Medicines (BeiGene) · Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
- CMP 001VidutolimodPhase 32 trials
Pfizer · Advanced Malignancies, NSCLC, Ovarian Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from BeOne Medicines (BeiGene).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.